The expression of FSP1 provides a strategy for predicting the sensitivity and efficacy of cancer cells to ferroptosis-inducing chemotherapies, as well as directions for developing FSP1 inhibitors to treat cancer and overcome ferroptosis resistance in many cancers. This evidence concerns the gene AIFM2 and cancer.